Source comparison
BPC-157 vs. Other Peptides: A Regulatory Comparison
It can be helpful to see how BPC-157's status compares to other well-known peptides. Each compound has its own story and regulatory pathway. Our experience shows that researchers who understand this broader context are better equipped to plan their studies. He
This comparison does not assign a generated winner or score.
- It can be helpful to see how BPC-157's status compares to other well-known peptides. Each compound has its own story and regulatory pathway. Our experience shows that researchers who understand this broader context are better equipped to plan their studies. Here’s a quick comparison:
- BPC-157
- Banned (S0 Unapproved Substances)
- Category 2 (Insufficient data for inclusion)
- Tissue repair, gut health, anti-inflammation
- TB-500
- Banned (S2 Peptide Hormones)
- Wound healing, recovery, cell migration
- Ipamorelin
- Category 1 (Approved for compounding)
- Growth hormone release, metabolism
- GHK-Cu
- Not Banned
- Not explicitly listed; common in cosmetics
- Skin health, collagen synthesis, anti-aging
- This table makes the complexity immediately apparent. You have compounds like Ipamorelin, which are banned by WADA but still available for compounding, and others like GHK-Cu, which are largely unregulated in both spheres. BPC-157 and TB-500 sit in a similar boat—restricted by both WADA and the FDA's compounding rules, yet still vital for preclinical research.